drugset / Trial / NCT02674776
Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a multi-center, double-blind, randomized, parallel controlled trial. Patients with acute gout will be enrolled and randomly allocated into 2 groups: HuZhen capsule treatment group and Placebo control group. Randomization codes were established by the biostatistician. Observe will be followed for 3 days (72 hours) after the onset. Change of VAS score from baseline, proportion of improvement with damp-heat retention, change in C-reactive protein (CRP) and erythrocyte sedimentation rate ( ESR) from baseline, change in white blood cell count in whole blood cell analysis from baseline, and the number of adverse events will be monitored and compared between each groups.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-12
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HuZhen Capsule | Unknown | 1.6 g | — |